GGrantIndex
← Search

CANCER CENTER CORE SUPPORT GRANT

$3,263,495P30FY2001CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

This is a five year CCSG renewal (years 24 through 29 requested) for the 298 member Jonsson Comprehensive Cancer Center at UCLA. Major changes have been introduced into the Cancer Center to strengthen clinical research, foster increased collaboration and promote translational research, since the arrival of the new Director, Judith G. Gasson, P.h.D. in September of 1995. Changes in the Program Areas include a new program in Signal Transduction in the Division of Basic Research and complete re-organization of the Clinical/Translational Program Areas into: (i) Breast and Women's Reproductive Cancers, (ii) Hematopoietic Malignancies, BMT and Stem Cells, (iii) Prostate Oncology and (iv) Solid Tumor Oncology. In addition, the program areas in the Division of Prevention and Control Research have been re-organized into Healthy and at-Risk Populations and Patients and Survivors. Renovation and creation of over 19,000 square feet of new laboratory space, along with completion of the second competitive cancer center space review facilitated the recruitment of fifteen outstanding new faculty and allowed the re-assignment of space within the building based upon merit and to facilitate productive interactions. Clinical Research has been strengthened considerably by increased space and support for the Clinical Research Unit. Accrual of patients to clinical trials has increased substantially and the quality of research has been improve by implementation and subsequent approval of our Clinical Protocol Review and Monitoring System. A Clinical Trials Development has been established to facilitate the conduct of phase 1 trials, particularly those arising from translational research within the Cancer Center. Finally, a community based/UCLA Oncology Research Network has been established throughout Southern California to provide state-of-the-art care and access to clinical trials to patients in their local communities.

View original record on NIH RePORTER →